Modelling expenses for multiple sclerosis treatment

  title={Modelling expenses for multiple sclerosis treatment},
  author={Anna Mokrova and Susanna S. Sologova and V. I. Ignatyeva},
Modern theory of multiple sclerosis requires substantial state expenditures which needs thorough clinical and economic implications assessment of introducing novel drugs in this disease treatment. 


Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
An Excel-based model was developed to compare the relative effectiveness and cost components of relapses, disability progression, and DMDs in the treatment of RRMS over a 2-year time horizon and found that glatiramer acetate had the least favorable cost-effectiveness and interferon betas had the most favorable costs per relapse avoided.
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis
It is concluded that HSCT could potentially achieve an acceptable level of cost-effectiveness, however, caution should be exercised as large, high-quality RCTs comparing HSCT versus mitoxantrone are necessary to validate these findings.
Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
Based on the CAM, cladribine tablets were projected to robustly save modelled drug-associated costs in comparison to fingolimod, natalizumab and their mix in Finland.
A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis
A systematic review of 11 disease-modifying drugs used for treatment of adult patients diagnosed with relapsing-remitting MS showed that alemtuzumab can be considered as more effective and less costly than the other treatment alternatives.
The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil
In the public health system of Brazil, disease modifying therapies currently represent almost all of the total direct costs of multiple sclerosis treatment, highlighting the need for cost-effectiveness studies comparing these technologies to those already available.
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
Based on traditional cost-effectiveness thresholds in Canada, DMF can be considered a cost-effective option compared to other first-line DMTs.
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Evaluating the cost effectiveness of four disease modifying treatments for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom found uncertainty around point estimates was substantial and price was the key modifiable determinant of the cost effective of these treatments.
The cost effectiveness and budget impact of natalizumab for formulary inclusion
It is found that natalizumab has been shown to be relatively cost effective in the treatment of both conditions from a payer perspective; the therapy adds a new option for those patients for whom conventional treatment was unsuccessful.